Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 57,900 shares, a decline of 37.8% from the August 15th total of 93,100 shares. Approximately 7.4% of the shares of the stock are short sold. Based on an average trading volume of 76,000 shares, the short-interest ratio is currently 0.8 days.
Vaccinex Stock Performance
Shares of VCNX opened at $5.61 on Friday. Vaccinex has a 12-month low of $4.21 and a 12-month high of $51.98. The company has a market cap of $8.89 million, a PE ratio of -0.07 and a beta of 0.99. The stock has a 50-day moving average price of $5.86 and a 200-day moving average price of $6.36.
Vaccinex (NASDAQ:VCNX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.
Insider Activity at Vaccinex
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC grew its position in shares of Vaccinex, Inc. (NASDAQ:VCNX – Free Report) by 86.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the period. AIGH Capital Management LLC owned about 6.90% of Vaccinex worth $707,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.11% of the company’s stock.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
Further Reading
- Five stocks we like better than Vaccinex
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- ESG Stocks, What Investors Should Know
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.